The integration of the two companies will also include Clintara's C-VISA Subject Eligibility Validation program designed to ensure appropriate patients are enrolled in clinical trials.
Founded in 2009, privately-held Clintara's methodology and technology features audio-digital pen recordings of site-based interviews and site-independent "dual" scoring reviews. The Clintara surveillance strategy can improve ratings precision and the data integrity of clinical trials.
Following the integration of the two companies, the Clintara leadership will assume expanded roles within Bracket. Clintara founder Steven Targum will become the Scientific Director of Bracket and will work closely with Bracket's SVP and Chief Medical Officer, David Daniel. Clintara CEO Colin Bower will also become VP, Scientific Services and will work with the Bracket leadership team and Scientific Advisory Board on ways to improve the conduct of clinical trials. Clintara has conducted over 60 trials which have included 23,000 screens at over 2,200 sites around the world.
The acquisition comes two years after private equity group Parthenon Capital Partners bought Bracket from US pharmacy benefits manager Express Scripts. Back in 2011, Bracket was created when United BioSource merged its clinical technologies and specialty clinical services group.
Bracket now has seven offices and more than 500 employees worldwide.